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Electrical and pharmacological cardioversion (ECV, PCV) are important treatment options for 
symptomatic patients with recent onset atrial fibrillation (AF). RHYTHM-AF is an 
international registry of present-day cardioversion providing information that is not currently 
available on country differences and acute and long-term arrhythmia outcome of ECV and 
PCV. 
 
Methods and results 
3940 patients were enrolled, of whom 75% underwent CV. All patients were followed for 2 
months. There were large variations concerning mode of CV used, ECV being heterogeneous. 
Choice of PCV drug depended on clinical patient profile. Sinus rhythm was restored in 89.7% 
of patients by ECV and in 69.1% after PCV. Among patients not undergoing CV during 
admission, 34% spontaneously converted to sinus rhythm within 24 hours. ECV was most 
successful in patients pretreated with antiarrhythmic drugs (mostly amiodarone). PCV was 
enhanced by class Ic antiarrhythmic drugs; conversion rate on amiodarone was similar to that 
seen with rate control drugs. Female patients and those with paroxysmal and first detected AF 
as well as those without previous ECV responded well to PCV. The median duration of 
hospital stay was 16.2 and 24.0 hours for ECV and PCV patients, respectively. There were 
very few CV-related complications regardless of mode of CV. Chronic maintenance of sinus 
rhythm was enhanced in patients on chronic antiarrhythmic drugs, beta-blockers or inhibitors 




Mode of CV varied significantly, but both PCV and ECV were safe and effective. Class Ic 
drugs were most effective conversion drugs, but amiodarone is used most frequently despite 
providing merely rate control rather than foreshortening time to conversion.  
 




Atrial fibrillation (AF) is common and often accompanied by incapacitating 
symptoms.(1) The management of newly detected atrial fibrillation (AF) relies on appropriate 
antithrombotic management, detection and treatment of associated cardiovascular diseases, 
and symptom alleviation.(2) Since cardiovascular outcomes are similar in AF patients 
receiving both rate and rhythm control therapy, rate control is often the therapy of choice 
among physicians.(3, 4) Without adequate symptom relief, restoration of sinus rhythm 
becomes the eventual target.  
Cardioversion (CV) of AF is critical in alleviating symptoms acutely. Both 
pharmacological (PCV)(5, 6) and electrical cardioversion (ECV)(7) are widely accepted. PCV 
(including the “pill-in-the-pocket-approach”) is frequently performed in patients with 
recurrent AF, but caution is needed to avoid complications, such as acute heart failure, 
bradycardia, and ventricular arrhythmias.(5, 8-10) ECV is more effective than PCV, 
especially in persistent AF, but often requires hospitalization, anesthesiology support and 
greater recovery time.(11) Both are generally safe and effective in producing sinus rhythm 
acutely.(9)  
Recommendations, treatments, and goals of rhythm control are clearly given in the 
guidelines;(2) however, contemporary observational data on cardioversion practices are 
scarce.(9, 12-14) The RHYTHM-AF study described clinical routines and outcomes of CV in 
patients with AF considered for rhythm control.(15) The present paper describes the main 
study results, focusing on patient characteristics, treatment patterns, and outcomes related to 





Design and study population 
The design of the study has been reported in detail previously.(15) Briefly, RHYTHM-
AF is a prospective international multicenter observational study of 3940 patients with AF for 
whom CV was considered. The protocol did not recommend or discourage any treatments, 
procedures, or examinations that were not part of routine care. Informed consent was obtained 
from all patients and the study was conducted in accordance with principles of Good Clinical 
Practice and was approved by the appropriate institutional review boards and regulatory 
agencies. All data were collected electronically in a central database and follow-up data were 
collected 60 days after enrollment. 
The study was sponsored by Merck & Co., Inc. and its subsidiaries. The Scientific 
Committee has the authority to make all decisions related to design, conduct, data 
interpretation and dissemination of study results. 
Endpoints 
PCV was considered successful if sinus rhythm or atrial rhythm was obtained within 
24 hours after its initiation. Time to sinus rhythm was noted separately. ECV was defined as 
successful if sinus rhythm was obtained and maintained for at least 10 minutes after the last 
shock. We grouped conversion drugs into Vaughan-Williams (16) Class Ic (flecainide, 
propafenone), and Class III drugs (almost exclusively amiodarone, and sotalol in only 2 
instances). Other drugs used for conversion as reported by physicians included almost 
exclusively the typical rate control drugs (i.e., digitalis, beta-blockers, and verapamil or 
diltiazem). 
Statistical analysis  
7 
Baseline variables were compared by mode of cardioversion, as well as by class of 
drug used for PCV using χ2 tests (categorical variables) and Kruskal-Wallis tests (continuous 
variables). Multivariable logistic regression was performed to detect (a) factors independently 
associated with success of ECV and PCV, as well as determinants of successful PCV on class 
Ic and class III antiarrhythmic drugs (AAD); and to detect (b) determinants of maintenance of 
sinus rhythm at 2 months in all patients discharged in sinus rhythm. Variables were included 
in the logistic regression for biological relevance and if shown significant (p<0.1) in 
univariate analysis. All statistical analyses were performed with SAS statistical software (SAS 




Patient characteristics  
Table I shows patient characteristics by mode of treatment. Patients undergoing ECV 
or no CV at all were more often admitted in cardiology wards; those receiving PCV were 
mostly treated in the emergency department. Hypertension, coronary artery disease and 
diabetes were the most prevalent associated comorbidities. Patients undergoing class Ic-PCV 
had the most favorable clinical profile. Persistent AF was the most frequent type of AF among 
ECV patients, whereas PCV patients predominantly had either first-detected or paroxysmal 
AF, nearly all presenting very early after AF onset.  
At enrollment, one-third of patients had a breakthrough arrhythmia, i.e. they were 
using prophylactic class Ic (8%) or class III AADs (23%). Among those who did not undergo 
CV, reasons for avoiding the intervention were spontaneous sinus rhythm, planned CV after 
discharge, spontaneous echo-contrast or left atrial thrombus on transesophageal 
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echocardiography (TEE), or uncertain duration of current AF episode duration (Figure 1). 
Palpitations were reported by 72% of PCV patients and only by 40% of ECV patients; in 
contrast shortness of breath was more frequent in ECV patients (44% vs. 29%). Standard 
echocardiography was performed most frequently in patients not receiving CV (61%) and 
least frequently in class Ic drug PCV patients (29%). Pre-procedural TEE was done mostly in 
patients undergoing ECV. 
Cardioversion characteristics and outcomes 
Overall, CV was performed a median of 4.0 (IQR 1.4-25.5) hours after admission, i.e. 
after 6 (2.4-40) hours for ECV and 1.7 (0.6-8.7) hours for PCV. Among patients undergoing 
class Ic PCV and class III PCV, treatment was administered at 1.1 (IQR 0.34-2.3) and 1.5 
(IQR 0.37-25) hours, respectively. Use of antithrombotic treatment is summarized in Figure 2. 
Overall, CV was successful in 82.6% of the patients. ECV (89.7%) was more 
successful than PCV (69.1%). Class Ic and class III PCV (amiodarone) was successful in 77% 
and 68% of cases, whereas 57% of patients treated by non-antiarrhythmic drugs converted to 
sinus rhythm. Intravenous and oral PCV were successful in 72% and 63% of patients, 
respectively.  
The increase in the use of class III drugs after cardioversion was significant, mainly 
due to change in amiodarone prescriptions. Far fewer patients were managed long term with 
class Ic drugs. The rise in class III and Ic drug prescription after conversion was especially 
apparent in patients undergoing class III (amiodarone) and class Ic drug conversion, 
respectively (Figure 3). 
The median duration of hospital stay was 16.2 (IQR 5.2-69) and 24.0 hours (IQR 7.6-
87.3) for ECV and PCV patients, respectively. It was longer in patients undergoing Class III 
PCV (57.5 hours [range: 15.3-162.3]) compared to Class Ic PCV (8.4 hours [range: 4.4-
9 
22.6]). The duration of hospitalization was longer in patients with unsuccessful compared to 
successful CV: 22.8 vs. 15.8 for ECV and 34.5 vs. 20.0 hours for PCV, respectively. 
There were few complications experienced during the first 5 days after admission, 
regardless of CV strata (Table II). Two months after admission, 64.3% of patients were in 
sinus rhythm. Factors independently associated with successful ECV or PCV and 
maintenance of sinus rhythm at 2 months follow-up, after multivariate adjustment, are 
presented in Table III. 
 
DISCUSSION 
RHYTHM-AF provides new comprehensive data on clinical cardioversion of AF. 
Herein we show that CV modality applied depends on type and duration of AF, cardioversion 
history, and patient symptoms. Class Ic drugs are most effective but their use is relatively 
limited to healthier patients. Of note, amiodarone does not perform better for PCV than the 
typical rate control drugs in accelerating conversion, but is used most frequently, especially in 
patients in whom class Ic drugs are contraindicated. We observed PCV to shorten time to 
conversion and if successful, also reduce time spent in the hospital after cardioversion. Early 
cardiovascular complications related to CV appear infrequent.  
Amiodarone pretreatment and the presence of an anesthesiologist were associated with 
successful ECV. Pretreatment with amiodarone, but also with flecainide, ibutilide, 
propafenone, or sotalol may enhance success of ECV. (2, 18) In Rhythm-AF, amiodarone was 
used most frequently, likely due to the fact that pretreatment with other agents maybe unsafe, 
while rational application of amiodarone always includes pretreatment for its remarkable 
pharmacokinetics. The presence of an anesthesiologist during ECV also appeared to enhance 
cardioversion. This may relate to deeper sedation with less adrenergic activation upon 
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awakening, use of less arrhythmogenic sedation, or to increased focus of the healthcare 
provider on the cardioversion itself with more aggressive application of repeated shocks as 
needed. In light of these observations, institutions with below average ECV cardioversion 
rates may consider revising local procedure, type of sedation, engaging anesthesiologist 
assistance, or amiodarone pretreatment.(2,11) 
PCV shortens time to conversion (Figure 4), thereby effectively limiting symptoms 
and reducing time spent in the hospital. Especially class Ic drugs accelerated conversion to 
sinus rhythm and were also associated with a significantly higher conversion rate within 24 
hours compared to amiodarone and the rate control drugs. Conversion to sinus rhythm was 
independently associated with gender, type of AF, and history of ECV. It is uncertain why 
women responded better to PCV, although pharmacokinetic differences may have played a 
role as dose adjustments are rarely performed in clinical practice. It is well known that 
paroxysmal AF patients respond much better to PCV than persistent AF; the same may hold 
for first-detected AF, which may include a significant number of self-terminating AF. Prior 
ECV appeared to be associated with a reduced conversion rate of PCV. Apparently, a 
previous ECV may indicate more resistant AF precluding successful conversion when PCV is 
chosen. 
Drug choice for PCV depended on patient characteristics, with amiodarone mainly 
used in patients with higher disease burden. Indeed, a relatively high prevalence of CHA2DS2-
VASc score >1 among amiodarone PCVs was observed, compared to all other PCVs. 
Specifically the prevalence of heart failure, coronary artery disease and valvular heart disease 
was relatively high in amiodarone PCVs. A similar disease burden was seen among no CV 
patients, a potential reason for deferring CV.  
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In patients with structural heart disease, amiodarone is one of the recommended 
conversion drugs (2); however, when absent, class Ic drugs are preferred since cardioversion 
with amiodarone occurs many hours later than with flecainide or propafenone (19) (Figure 4). 
Despite recommendations, amiodarone and even typical rate control drugs were used in many 
patients, which may have led to avoidable CV failure, the need for back-up ECVs, and 
prolonged hospitalisation. Of note, amiodarone performed similarly to rate control drugs, 
rendering its application for shortening conversion time futile. On the other hand, amiodarone 
provides acute rate control which is crucial in the wait-and-see approach to CV.  
Oral propafenone appeared less effective in producing sinus rhythm than flecainide, 
perhaps due to the relatively low dose of oral propafenone used. Whereas flecainide was 
applied as recommended, (2,5) propafenone was underdosed (median dose 300 mg). It is 
uncertain (but not very likely for short timelines) whether propafenone underdosing related to 
recent clinical experience indicating that especially home cardioversion with 600 mg 
propafenone can produce significant adverse events despite a previous uneventful in-hospital 
drug trial. (10) 
Before enrollment, two thirds of patients had one or more previous AF episodes, of 
whom only one third had a breakthrough arrhythmia, i.e. a new AF episode while using an 
antiarrhythmic drug, consistent with previous research. (9) This suggests that most patients do 
not use an antiarrhythmic to prevent new attacks between episodes, presumably because of a 
low attack rate, experiencing the first ever cardioversion (two-thirds of included patients), or 
because of the risks of chronic antiarrhythmic drug prophylaxis. Finally patient’s preference 
may have played a role in not starting antiarrhythmic drug prophylaxis after previous attack(s) 
before study entry. Although breakthrough AF may be considered more severe to treat, add-
on class Ic drug treatment was similarly effective compared to class Ic conversion in drug-free 
patients. Patients on chronic drug treatment with breakthrough AF frequently add on 
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flecainide or propafenone at home, although, pill-in-the-pocket propafenone has been reported 
to be associated with adverse events. (10) Nevertheless, many patients with breakthrough AF 
fare well with such a strategy, thus avoiding hospitalizations. 
Patients using AAD both at admission and discharge maintained sinus rhythm in the 
short term (2 months) significantly better than those who were put on these agents only at 
discharge or who were kept off AAD. In line with recent studies, (20,21) the registry supports 
the notion that pretreatment and continued antiarrhythmic drug prophylaxis is more effective 
than other antiarrhythmic drug strategies or no prophylaxis. Additionally, we observed that 
beta-blockers and inhibitors of the renin-angiotensin system reduced short term recurrences. 
Several previous studies have shown that in the presence of amiodarone, angiotensin receptor 
blockers (ARB) and ACE-inhibitors (ACE-i) help to prevent recurrences after cardioversion 
both in paroxysmal as well as persistent AF. (2) In the present study, the effect of ACE-i/ARB 
was independent of continued antiarrhythmic drug use. This may relate to the relatively short 
term follow-up of 2 months during which mainly subacute recurrences (whose mechanism 
may differ from that of recurrences occurring later on during follow-up) happen. (11) 
Aldosterone antagonists have also been reported to reduce recurrences of AF after ECV, (22) 
but this effect could not be studied since few used these agents in this study. First detected AF 
was observed to be associated with a worse short term arrhythmia prognosis than persistent 
AF, for which we do not have an explanation (Table III). Likewise, it is uncertain why stable 
angina pectoris or absence of AF symptoms would be associated with better rhythm outcome 
at 2 months. 
This study had several strengths, including its large size, the short period of overall 
study time enhancing robustness of the data, the standardized collection of data, and the broad 
scope of patients. It was not without limitations, including lack of full control on 
representativeness of sites and on consecutiveness of patients as well as a relatively short 
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follow-up period. Nevertheless, it offers insight into the importance of considering patient’s 
preferences concerning mode of CV.   
Conclusions 
In current practice, pharmacological and electrical cardioversion are safe and effective. 
Electrical cardioversion seems well developed, but improvement may be obtained through 
pharmacological pretreatment. The class Ic drugs are most effective as acute conversion 
drugs. Amiodarone enhances electrical cardioversion and maintenance of sinus rhythm, but as 
a conversion drug it is not more effective than the typical rate control drugs. Arrhythmia 
outcome after cardioversion is a strong driver for admission duration and hence improvement 
of cardioversion by new drugs and combination of drugs and electrical cardioversion may 
reduce costs incurred by cardioversion. Finally, accounting for patients’ preferences for one 
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Figure 1: Modes of cardioversion and procedural characteristics 
CV: cardioversion; PCV: pharmacological cardioversion; ECV: electrical cardioversion; TEE: 
transesophageal echocardiography; AAD: antiarrhythmic drug; IV: intravenous; PM: 
pacemaker;  
Figure 2: Use of anti-thrombotic drugs at enrollment 
Percentages add up to > 100% because some patients used combinations of antithrombotic 
drugs. APD: antiplatelet drug; ATT: antithrombotic treatment; ECV: electrical cardioversion; 
PCV: pharmacological cardioversion; VKA: vitamin K agonist  
Figure 3: Change of antiarrhythmic treatment after inclusion: comparison of the distribution 
of antiarrhythmic drugs used at admission and discharge in all patients as well as per type of 
cardioversion 
Figure 4: Time to conversion on intravenous and oral AAD by type of drug 
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(ALL CV / 
no CV) 
P-value  
(ECV / no 
CV) 
P-value 
(PCV / no 
CV) 
P-value 
ECV / PCV 
DEMOGRAPHICS          
Number of patients (%) 3940 2972 (75) 1946 (49) 1026 (26) 968 (25)     
Age (years) 66±12 66±12.2 67±11 66±14.2 67±12 0.24 0.17 0.59 0.58 
Female sex, n (%) 1479 (37.6) 1108 (37,3) 633 (32.5) 475 (46.3) 371 (38.4) 0.53 <0.01 <0.001 <0.0001 
BMI (kg/m2) 28.4±61  28.3±5.5 28.6±5.8 27.8±4.9 28.7±7.7 0.57 0.08 0.13 <0.001 
Heart Rate (beats per 
minute) 
106±31 105±31 95±27 126±28 108±31 <0.05 <0.0001 <0.0001 <0.0001 
SITE OF ADMISSION          
   Emergency department 33.0% 34.6% 15.9% 70.1% 28.1% <0.001 <0.0001 <0.0001 <0.0001 
   Cardiology ward 46.1% 45.0% 59.2% 17.9% 49.6% <0.05 <0.0001 <0.0001 <0.0001 
   Intensive care unit 5.1% 4.8% 4.3% 5.9% 5.7% 0.29 0.09 0.81 <0.05 
   Other 15.8% 15.5% 20.6% 6.0% 16.5% 0.47 <0.01 <0.0001 <0.0001 
COMORBIDITY          
Hypertension, n (%) 62.4% 62.2% 62.5% 61.7% 62.8% 0.74 0.87 0.61 0.67 
Systolic blood pressure 
(mmHg) 
131.6±20.3 131.7±20.4 131.1±19.0 132.9±22.7 131.5±19.8 0.72 0.85 0.24 0.11 
19 
Diastolic pressure (mmHg) 80.0±13.3 80.2±13.7 80.2±12.9 80.1±15.0 79.5±12.0 0.07 <0.05 0.33 0.55 
Coronary artery disease, n 
(%) 
893 (22.7) 663 (22.3) 457 (23.5) 206 (20.1) 230 (23.8) 0.35 0.87 <0.05 <0.05 
Valvular heart disease, n (%) 539 (13.7) 395 (13.3) 285 (14.6) 110 (10.7) 144 (14.9) 0.21 0.87 <0.01 <0.01 
Diabetes mellitus, n (%) 679 (17.3) 485 (16.3) 323 (16.6) 162 (15.8) 194 (20.3) <0.01 <0.05 <0.01 0.57 
HF NYHA I-II 11.3% 11.3% 13.1% 8.1% 11.1% 0.81 0.12 <0.05 <0.0001 
HF NYHA III-IV 3.7% 3.5% 4.0% 2.4% 4.4% 0.16 0.58 <0.05 <0.05 
Chronic obstructive 
pulmonary disease 
7.8% 7.7% 5.8% 11.2% 8.2% 0.62 <0.05 <0.05 <0.0001 
Thromboembolism, n (%)  239 (6.1) 180 (6.1) 126 (6.5) 54 (5.3) 59 (6.1) 0.97 0.69 0.42 0.19 
History of Stroke 2.9% 2.8% 3.0% 2.5% 3.1% 0.67 0.90 0.41 0.41 
History of TIA 2.5% 2.5% 2.6% 2.4% 2.3% 0.74 0.65 0.97 0.67 
Peripheral vascular disease 6.3% 6.2% 5.6% 7.1% 6.7% 0.56 0.27 0.70 0.11 
Hemorrhagic complication, 
n (%)  
47 (1.2) 32 (1.1) 20 (1.1) 12 (1.2) 15 (1.6) 0.24 0.23 0.45 0.76 
Hyperthyroidism 4.3% 4.6% 5.3% 3.3% 3.2% 0.07 <0.05 0.92 <0.05 
CHA2DS2-VASc >1 69.7% 69.1% 69.3% 68.0% 71.4% 0.20 0.38 0.11 0.35 
AF CHARACTERISTICS          
1st detected AF 32.1% 31.3% 23.1% 46.8% 34.6% 0.05 <0.0001 <0.0001 <0.0001 
Paroxysmal AF 29.4% 28.8% 21.7% 42.4% 31.2% 0.16 <0.0001 <0.0001 <0.0001 
Persistent AF 31.2% 33.0% 45.5% 9.2% 25.5% <0.0001 <0.0001 <0.0001 <0.0001 
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Total AF history (years) 4.5±5.5 4.6±5.5 4.4±5.5 5.0±5.5 4.5±5.2 0.61 0.98 0.15 0.06 
Current episode <48h, n (%) 1575 (50.7) 1235 (50.6) 419 (27.0) 816 (91.6) 340 (51.4) 0.69 <0.0001 <0.0001 <0.0001 
Previous Cardioversion 33.2% 35.1% 38.6% 28.5% 27.4% <0.0001 <0.0001 0.59 <0.0001 
  Previous ECV 45.2% 47.3% 55.8% 22.4% 37.9% <0.001 <0.0001 <0.0001 <0.0001 
  Previous PCV 28.5% 28.5% 15.7% 64.3% 28.7% 0.94 <0.0001 <0.0001 <0.0001 
Currently symptomatic, n 
(%) 
3338 (85.0) 2526 (85.0) 1574 (80.9) 952 (92.8) 812 (84.8) 0.91 <0.01 <0.0001 <0.0001 
ECHOCARDIOGRAPHY 
(n=2024) 
         










<0.0001 <0.0001 <0.0001 
Left atrial diameter (mm) 44.2±7.4 44.5±7.5 45.6±7.1 42.0±7.7 43.6±7.2 <0.05 <0.0001 <0.01 <0.0001 
Left atrial diameter > 40mm 55% 55% 60% 43.4% 55.3% 0.82 0.09 <0.001 <0.0001 
LVEF <40% 19.7% 20.5% 22.7% 15.5% 18% 0.21 <0.05 0.30 <0.01 
MEDICATION AT 
INCLUSION (n=3926) 
         
Vitamin K antagonist, n (%) 2206 (56.1) 1744 (58.7) 1514 (77.8) 230 (22.4) 462 (48.3) <0.0001 <0.0001 <0.0001 <0.0001 
Heparin, n (%) 340 (8.6) 221 (7.4) 144 (7.4) 77 (7.5) 118 (12.2) 0.0001 <0.0001 <0.001 0.92 
No antithrombotic 
treatment, n (%) 
796 (20.3) 583 (19.6) 1541 (7.9) 429 (41.8) 213 (22.3) 0.07 <0.0001 <0.0001 <0.0001 
ACE-inhibitor / ARB, n (%) 2171 (55.1) 1641 (55.2) 1157 (59.5) 484 (47.2) 530 (54.8) 0.80 <0.05 <0.001 <0.0001 
Beta-blocker, n (%) 1648 (42) 1247 (42.0) 1008 (51.9) 239 (23.3) 401 (42.0) 1.00 <0.0001 <0.0001 <0.0001 
21 
Digoxin or digitoxin 9.0% 8.9% 12.0% 3.0% 9.2% 0.77 <0.05 <0.0001 <0.0001 
Verapamil or diltiazem 3.3% 3.3% 3.8% 2.2% 3.4% 0.83 0.59 0.11 <0.05 
Flecainide or propafenone 8.0% 8.1% 6.6% 10.8% 8.0% 0.90 0.19 <0.05 <0.0001 
Sotalol 3.6% 3.8% 4.3% 2.8% 2.9% 0.22 0.08 0.89 <0.05 
Amiodarone 16.8% 16.9% 22.5% 6.2% 16.6% 0.86 <0.001 <0.0001 <0.0001 
Dronedarone 2.7% 2.7% 3.8% 0.8 2.5% 0.72 0.08 <0.01 <0.0001 
 
 
















(Ic / III) 
P-value 
(Ic / other) 
P-value  
(III / other) 
DEMOGRAPHICS       
Number of patients (%) 306 (8) 489 (12) 231 (6)    
Age (years) 61±14 70±13 65±15 <0.0001 <0.01 <0.001 
Female sex, n (%) 130 (42.5) 241 (49.3) 104 (45.0) 0.06 0.56 0.29 
BMI (kg/m2) 27.4±4.7 28.2±5.0 27.8±5.1 <0.05 0.27 0.46 
Heart Rate (beats per minute) 125±26 125±28 130±27 0.80 <0.05 0.06 
SITE OF ADMISSION       
22 
   Emergency department 81.4% 61.3% 73.6% <0.0001 <0.05 <0.01 
   Cardiology ward 14.7% 19.6% 18.6% 0.08 0.23 0.75 
   Intensive care unit 0.7% 11.7% 0.9% <0.0001 0.78 <0.0001 
   Other 3.3% 7.4% 6.9% <0.05 0.05 0.83 
COMORBIDITY       
Hypertension, n (%) 50.0% 69.9% 59.7% <0.0001 <0.05 <0.01 
Systolic blood pressure 
(mmHg) 
134.3±21.3 131.9±23.0 133.1±23.6 0.19 0.43 0.71 
Diastolic pressure (mmHg) 82.0±14.0 78.3±15.4 81.5±15.0 <0.01 0.66 <0.05 
Coronary artery disease, n (%) 27 (8.8) 137 (28.0) 42 (18.2) <0.0001 <0.01 <0.01 
Valvular heart disease, n (%) 12 (3.9) 70 (14.3) 28 (12.1) <0.0001 <0.001 0.42 
Diabetes mellitus, n (%) 34 (11.1) 90 (18.4) 38 (16.5) <0.01 0.07 0.52 
HF NYHA I-II 4.6% 9.2% 10.4% <0.05 <0.01 0.61 
HF NYHA III-IV 0.3% 4.3% 1.3% <0.001 0.19 <0.05 
Chronic obstructive pulmonary 
disease 
8.2% 12.9% 11.7% <0.05 0.17 0.65 
Thromboembolism, n (%)  7 (2.3) 28 (5.7) 19 (8.2) <0.05 <0.01 0.21 
History of Stroke 1.3% 2.9% 3.1% 0.15 0.16 0.90 
History of TIA 1.0% 2.3% 4.4% 0.19 <0.05 0.12 
Peripheral vascular disease 4.3% 9.4% 6.2% <0.01 0.33 0.15 
Hemorrhagic complication, n 4 (1.3) 6 (1.2) 2 (0.9) 0.92 0.63 0.66 
23 
(%)  
Hyperthyroidism 2.7% 3.5% 3.7% 0.56 0.54 0.90 
CHA2DS2-VASc >1 50.7% 79.3% 56.4% <0.0001 <0.001 <0.0001 
AF CHARACTERISTICS       
1st detected AF 35.9% 53.6% 46.8% <0.0001 <0.05 0.09 
Paroxysmal AF 54.6% 34.4% 43.3% <0.0001 <0.01 <0.05 
Persistent AF 8.8% 9.4% 9.1% 0.78 0.91 0.89 
Total AF history (years) 5.8±5.7 4.3±5.4 4.6±5.1 <0.01 0.05 0.32 
Current episode <48h, n (%) 280 (94.9) 348 (89.7) 188 (90.4) <0.05 <0.05 0.79 
Previous Cardioversion 38.2% 23.1% 26.8% <0.0001 <0.01 0.28 
  Previous ECV 23.9% 22.0% 20.2% 0.69 0.51 0.74 
  Previous PCV 68.5% 59.2% 66.2% 0.10 0.73 0.30 
Currently symptomatic, n (%) 299 (97.7) 437 (89.4) 216 (93.5) <0.0001 <0.05 0.07 
ECHOCARDIOGRAPHY 
(n=2024) 
      
TTE / TEE performed 28.8/ 3.3% 56.2/ 6.3% 34.2/ 6.9% <0.0001 / 
0.06 
0.18 / 0.05 <0.0001 / 
0.77 
Left atrial diameter (mm) 40.8±7.0 42.2±7.2 42.5±9.9 0.09 0.33 0.63 
Left atrial diameter > 40mm 37% 46% 41% 0.14 0.63 0.39 
LVEF <40% 1.1% 19% 19.7% <0.0001 <0.0001 0.88 
MEDICATION AT INCLUSION       
24 
(n=3926) 
Vitamin K antagonist, n (%) 64 (20.9) 114 (23.3) 52 (22.5) 0.43 0.66 0.81 
Heparin , n (%) 11 (3.5) 49 (10.0) 18 (7.8) <0.001 0.05 0.25 
No antithrombotic treatment, n 
(%) 
148 (48.4) 180 (36.8) 101 (43.7) <0.01 0.29 0.08 
ACE-inhibitor / ARB, n (%) 114 (37.3) 265 (54.2) 105 (45.5) <0.0001 0.06 <0.05 
Beta-blocker, n (%) 79 (25.8) 117 (23.9) 43 (18.6) 0.55 <0.05 0.11 
Digoxin or digitoxin 1.0% 4.3% 3.0% <0.01 0.08 0.41 
Verapamil or diltiazem 2.0% 2.2% 2.6% 0.78 0.62 0.77 
Flecainide or propafenone 21.2% 4.9% 9.5% <0.0001 <0.001 <0.05 
Sotalol 5.2% 1.4% 2.6% <0.01 0.13 0.27 
Amiodarone 2.3% 9.4% 4.8% <0.0001 0.11 <0.05 
Dronedarone 1.0% 0.6% 0.9% 0.56 0.89 0.70 
*)
 Class III drugs included amiodarone, in all but 7 cases of other class III drugs. 
#)
 Other Abbreviations: ACE-I: angiotensin-converting-enzyme 














           
Death     
≤ 5 days 1 (0.05%) 1 (0.10%) 1 (0.10%) 3 (0.08%) 
> 5 days ≤ 70 days 6 (0.31%) 7 (0.68%) 9 (0.93%) 22 (0.56%) 
> 70 days _  1 (0.10%) 2 (0.21%) 3 (0.08%) 
Thromboembolic Event     
≤ 5 days _ _ _ _ 
> 5 days ≤ 70 days 5 (0.26%) 4 (0.39%) 2 (0.21%) 11 (0.28%) 
> 70 days 4 (0.21%) _ _ 4 (0.10%) 
Heart Failure     
≤ 5 days 1 (0.05%) 1 (0.10%) _ 2 (0.05%) 
> 5 days ≤ 70 days 8 (0.41%) 4 (0.39%) 4 (0.41%) 16 (0.41%) 
> 70 days 1 (0.05%) _ _ 1 (0.03%) 
Major Bleeding     
≤ 5 days _ _ _ _ 
> 5 days ≤ 70 days _ 2 (0.19%) 3 (0.31%) 5 (0.13%) 
> 70 days 1 (0.05%) _ _ 1 (0.03%) 
Bradycardia / Hypotension     
≤ 5 days _ _ _ _ 
> 5 days ≤ 70 days 9 (0.46%) 4 (0.39%) 5 (0.52%) 18 (0.46%) 
> 70 days 3 (0.15%) 1 (0.10%) _ 4 (0.10%) 
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Table III. Factors independently associated with obtaining and maintaining sinus 
rhythm 
 OR 95% CI P 
ECV
a  
(n=1861)    
VKA before admission 0.558 0.367-0.849 0.006 
Amiodarone before admission (pretreatment) 1.557 1.04-2.33 0.03 
Anesthesiologist present at CV 1.634 1.188-2.248 0.003 
PCV
b 
(n=880)    
Female gender  1.439  1.055-1.961  0.0215  
AF type (Persistent AF as reference): 
1
st











Previous ECV 0.531  0.319-0.883  0.0147 
Heart Failure (No heart failure as reference):  
NYHA I-II 










Valvular heart disease 0.581  0.364-0.926  0.0224 
CLASS Ic PCV
c
(n=272)    
Female gender 2.263 1.072-4.779 0.0323 
AF type (Persistent AF as reference): 
1
st











Previous ECV 0.346 0.141-0.848 0.0203 
Chronic renal failure 0.080 0.015-0.425 0.0030 
CLASS III PCV
d 
(n=437)    
AF type (persistent AF as reference): 
1
st











Previous ECV 0.241 0.108-0.539 0.0005 
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COPD  0.522 0.287-0.949 0.0330 
AT 2 MONTHS FOLLOW-UP
e 
(n=2709)    
Height 1.013 1.003-1.024 0.0130 
Stable angina pectoris 1.438 1.029 – 2.008 0.0333 
No AF symptoms 1.388 1.062 – 1.813 0.0164 














BB at admission 1.323 1.045-1.675 0.0200 
AAD Use (no AAD as reference) 
Continuous treatment (admission + discharge) 










BB at discharge 1.398 1.107 – 1.765 0.0049 
ACE-i/ARB at discharge 1.469 1.235 – 1.747 <0.0001 
To maximize patients included in the multivariable analysis, for those who had missing 
durations of current AF episode, median values of all paroxysmal and persistent AF patients 
with known duration of current AF episode were used. Patients with unknown AF type were 
reclassified into paroxysmal AF if they were selected for PCV whereas all other patients with 
unknown type of AF were considered to have persistent AF. AAD: anti-arrhythmic drugs, 
ACE-i: ACE (angiotensin-converting-enzyme) inhibitors, ARB: angiotensin receptor blocker, 
VV_blood pressure, COPD: chronic obstructive pulmonary disease, ECV: electrical 
cardioversion, NYHA class: New York Heart Association functional classification PCV: 




Figure 1. Modes of Cardioversion and Procedural Characteristics 
CV: cardioversion; PCV: pharmacological cardioversion; ECV: electrical cardioversion; TEE: 
transesophageal echocardiography; AAD: antiarrhythmic drug; IV: intravenous; PM: 
pacemaker;  
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Figure 2. Use of antithrombotic drugs at enrollment  
 
Percentages add up to > 100% because some patients used combinations of antithrombotic 
drugs. APD: antiplatelet drug; ATT: antithrombotic treatment; ECV: electrical cardioversion; 













Figure 3. Change in antiarrhythmic treatment after inclusion: Distribution of 










Figure 4. Time to conversion on intravenous (panel A) and oral (panel B) 
antiarrhythmic drugs  
A. 
 
B.  
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